Sustainability in CGT: Can cell and gene therapy developers save the environment, while saving patients?

7 Jun 2022
Sustainability in CGT

From reducing plastic pollution in labs to slashing carbon from manufacturing processes, the cell and gene therapy industry must find ways to develop therapies in an environmentally responsible manner. In this infographic, which has been created in partnership with RegMedNet, discover the ways that developers can revolutionize their workflows to streamline the pharmaceutical industry into a cleaner and greener future.
Download Guide

Share this article

Brad N. Taylor, Ph.D.
Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry before joining Nucleus Biologics. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.